| Methods | Randomized controlled trial. |
| Participants | Prostate cancer patients with painful bone metastases, who received emasculate. Control group: 73 cases. Combined treatment group: 65 cases. |
| Interventions | Control group: 89Sr treatment by intravenous injection at the dose of 1.48‐2.22 MBq (40‐60 mu Ci)/kg. Combined treatment group: 89Sr at same dose as control group, plus 99Tc‐MDP 200mg by intravenous transfusion per day, total 5 times (the period of treatment). |
| Outcomes | Pain relief. Pain flares. Anodyne reduction. Duration of pain relief. Advance activity ability. |
| Notes | Information obtained from the abstract. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.